Laboratoire HRA Pharma SA

The FDA on Thursday approved Perrigo's Opill (norgestrel) for over-the-counter (OTC) use, making it the first hormonal oral contraceptive available in the US without a prescription. "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available non-prescription contraceptive methods in preventing unintended pregnancy," stated Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.Roughly half the 6.1 million pregnancies in the US each year are unplanned, according to the FDA. It said the OTC approval "is expected to remove barriers to access and reduce the risk of unintended pregnancies."The progestin-only drug was initially approved by the FDA for prescription use in 1973. The latest decision followed a 17-0 advisory panel vote earlier this year in favour of recommending Opill for approval despite questions over some data on its proper use. These included whether women with certain medical conditions that would ordinarily preclude them from taking oral contraceptives – such as those with breast cancer and undiagnosed vaginal bleeding – will follow the warnings and avoid the product.FDA scientists also questioned whether younger people and people with limited literacy would be able to properly follow the dosing directions. In addition, agency staff suggested that researchers likely used methods that exaggerated positive results for the drug.However, in its decision Thursday, the FDA said that studies showed that consumer understanding of information on Opill's drug facts label was "high overall and that a high proportion of consumers understood the label instructions, supporting their ability to properly use the drug when it is available as an [OTC] product." The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating. The agency noted that Opill is not for use as emergency contraception and does not prevent pregnancy after unprotected sex.Expected launch in early 2024The approval of Opill was granted to Laboratoire HRA Pharma, which was acquired by Perrigo last year for €1.8 billion ($2 billion). The company said the contraceptive would be available for purchase by early 2024, but would not provide specifics about pricing. However, Frédérique Welgryn, Perrigo's global vice president for women's health, said the company was committed to making the drug "accessible and affordable to women and people of all ages," adding it would also set up a consumer assistance programme to provide Opill at no cost to some women.Meanwhile, under a recent executive order by President Joe Biden, the federal government could soon take steps toward requiring insurers to cover OTC oral contraceptive medications.The FDA approval comes nearly three months after the Supreme Court blocked a controversial lower court order challenging access to the abortion drug mifepristone. The lower court sought to restrict access to mifepristone, after a district court judge in Texas ruled to toss the FDA's approval of the drug, which had been cleared for more than 20 years.

SILVER SPRING, Md., July 13, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy— the first daily oral contraceptive approved for use in the U.S. without a prescription. Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online. The timeline for availability and price of this nonprescription product is determined by the manufacturer. Other approved formulations and dosages of other oral contraceptives will remain available by prescription only. "Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research. "When used as directed, daily oral contraception is safe and is expected to be more effective than currently available nonprescription contraceptive methods in preventing unintended pregnancy." Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider. Almost half of the 6.1 million pregnancies in the U.S. each year are unintended. Unintended pregnancies have been linked to negative maternal and perinatal outcomes, including reduced likelihood of receiving early prenatal care and increased risk of preterm delivery, with associated adverse neonatal, developmental and child health outcomes. Availability of nonprescription Opill may help reduce the number of unintended pregnancies and their potential negative impacts. The contraceptive efficacy of norgestrel was established with the original approval for prescription use in 1973. HRA Pharma applied to switch norgestrel from a prescription to an over-the-counter product. For approval of a product for use in the nonprescription setting, the FDA requires that the applicant demonstrate that the product can be used by consumers safely and effectively, relying only on the nonprescription drug labeling without any assistance from a health care professional. Studies showed that consumer understanding of information on the Opill Drug Facts label was high overall and that a high proportion of consumers understood the label instructions, supporting their ability to properly use the drug when it is available as an over-the-counter product. When properly used, Opill is safe and effective. Opill should be taken at the same time every day; adherence to daily use at the same time of day is important for the effectiveness of Opill. Using medications that interact with Opill can result in decreased efficacy of Opill or the other medication, or both, potentially resulting in unintended pregnancy. The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating. Opill should not be used by those who have or have ever had breast cancer. Consumers who have any other form of cancer should ask a doctor before use. Opill also should not be used together with another hormonal birth control product such as another oral contraceptive tablet, a vaginal ring, a contraceptive patch, a contraceptive implant, a contraceptive injection or an IUD (intra-uterine device). Use of Opill may be associated with changes in vaginal bleeding patterns, such as irregular spotting and prolonged bleeding. Consumers should inform a health care provider if they develop repeated vaginal bleeding after sex, or prolonged episodes of bleeding or amenorrhea (absence of menstrual period). Individuals who miss two periods (or have missed a single period and have missed doses of Opill) or suspect they may be pregnant should take a pregnancy test. Consumers should discontinue Opill if pregnancy is confirmed. Opill is not for use as emergency contraception and does not prevent pregnancy after unprotected sex. Oral contraceptives do not protect against transmission of HIV, AIDS and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B and syphilis. Condoms should be used to prevent sexually transmitted diseases. The FDA granted the approval to Laboratoire HRA Pharma, recently acquired by Perrigo Company plc. Related Information Drugs@FDA: Opill Decisional Memo Opill (0.075mg Oral Norgestrel Tablet) Information The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Emergency contraceptive pills market insights - Continue Reading Technavio has announced its latest market research report titled Global Emergency Contraceptive Pills Market 2023-2027 Vendors: 15+, Including AbbVie Inc. | Afaxys Pharma LLC | Bayer AG | Combe Inc. | Foundation Consumer Healthcare LLC | Gedeon Richter Plc | HLL Lifecare Ltd. | Knoll Healthcare Pvt. Ltd. | Laboratoire HRA Pharma SAS | Lupin Ltd. | Mankind Pharma Ltd. | Morepen Laboratories Ltd. | Perrigo Co. Plc | Pfizer Inc. | Piramal Enterprises Ltd. | Sun Pharmaceutical Industries Ltd. | Syzygy Healthcare LLC | Teva Pharmaceutical Industries Ltd., among others Coverage: Key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: Distribution Channel (Retail stores and Online stores), Type (Combination pills and Progesterone pills), and Geography (North America, Europe, Asia, and Rest of World (ROW)) To understand more about the emergency contraceptive pills market, request a sample report The emergency contraceptive pills market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects. Why Buy? Add credibility to the strategy Analyzes competitor's offerings Get a holistic view of the market Grow your profit margin with Technavio- Buy the Report In 2017, the emergency contraceptive pills market was valued at USD 831.35 million. From a regional perspective, North America held the largest market share, valued at USD 281.00 million. The emergency contraceptive pills market size is estimated to grow by USD 258.7 million from 2022 to 2027 at a CAGR of 4.83% according to Technavio. Emergency contraceptive pills market insights - Customer Landscape To help companies evaluate and develop growth strategies, the report outlines – Key purchase criteria Adoption rates Adoption lifecycle Drivers of price sensitivity For highlights on customer landscape analysis, download a sample ! Global emergency contraceptive pills market - Vendor Insights The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including - AbbVie Inc. - The company offers an emergency contraceptive pill, namely Liletta. Afaxys Pharma LLC - The company offers emergency contraceptive pills namely Annovera. Bayer AG: The company offers emergency contraceptive pills namely Yasmin. Combe Inc.: The company offers emergency contraceptive pills namely Preventeza. Global emergency contraceptive pills market – Market Dynamics Major drivers - Rise in the number of initiatives to create awareness Increase in unplanned pregnancies Ease of online purchase Key challenges - Local governments limiting access to emergency contraceptive pills Consumption and side effects Availability of alternative methods of contraception Drivers and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report! What are the key data covered in this emergency contraceptive pills market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the Emergency Contraceptive Pills Market between 2023 and 2027 Precise estimation of the size of the Emergency Contraceptive Pills Market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the Emergency Contraceptive Pills Market industry across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of Emergency Contraceptive Pills Market vendors Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports: The female contraceptive market is estimated to grow at a CAGR of 5.32% between 2022 and 2027. The size of the market is forecasted to increase by USD 5,142.22 million. This report extensively covers market segmentation by distribution channel (offline and online), product (female contraceptive devices and female contraceptive drugs), and geography (North America, Europe, APAC, South America, and the Middle East and Africa). The emergency food market size is expected to decline by USD 2.88 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.23%. This report extensively covers segmentation by product type (ready-to-eat meals, non-perishable pasteurized milk, infant food, dried food, and others), distribution channel (offline and online), and geography (North America, Europe, APAC, South America, and Middle East and Africa). Table of contents 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel Exhibit 06: Executive Summary – Chart on Market Segmentation by Type Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global emergency contraceptive pills market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global emergency contraceptive pills market 2017 - 2021 ($ million) 4.2 Distribution channel Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Distribution channel Segment 2017 - 2021 ($ million) 4.3 Type Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Distribution Channel 6.1 Market segments Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%) Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%) 6.2 Comparison by Distribution Channel Exhibit 32: Chart on Comparison by Distribution Channel Exhibit 33: Data Table on Comparison by Distribution Channel 6.3 Retail stores - Market size and forecast 2022-2027 Exhibit 34: Chart on Retail stores - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Retail stores - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Retail stores - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Retail stores - Year-over-year growth 2022-2027 (%) 6.4 Online stores - Market size and forecast 2022-2027 Exhibit 38: Chart on Online stores - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Online stores - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Online stores - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Online stores - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Distribution Channel Exhibit 42: Market opportunity by Distribution Channel ($ million) 7 Market Segmentation by Type 7.1 Market segments Exhibit 43: Chart on Type - Market share 2022-2027 (%) Exhibit 44: Data Table on Type - Market share 2022-2027 (%) 7.2 Comparison by Type Exhibit 45: Chart on Comparison by Type Exhibit 46: Data Table on Comparison by Type 7.3 Combination pills - Market size and forecast 2022-2027 Exhibit 47: Chart on Combination pills - Market size and forecast 2022-2027 ($ million) Exhibit 48: Data Table on Combination pills - Market size and forecast 2022-2027 ($ million) Exhibit 49: Chart on Combination pills - Year-over-year growth 2022-2027 (%) Exhibit 50: Data Table on Combination pills - Year-over-year growth 2022-2027 (%) 7.4 Progesterone pills - Market size and forecast 2022-2027 Exhibit 51: Chart on Progesterone pills - Market size and forecast 2022-2027 ($ million) Exhibit 52: Data Table on Progesterone pills - Market size and forecast 2022-2027 ($ million) Exhibit 53: Chart on Progesterone pills - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Progesterone pills - Year-over-year growth 2022-2027 (%) 7.5 Market opportunity by Type Exhibit 55: Market opportunity by Type ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 57: Chart on Market share by geography 2022-2027 (%) Exhibit 58: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 59: Chart on Geographic comparison Exhibit 60: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 61: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 62: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 63: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 64: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 65: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 China - Market size and forecast 2022-2027 Exhibit 81: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on China - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on China - Year-over-year growth 2022-2027 (%) 9.9 Germany - Market size and forecast 2022-2027 Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.10 France - Market size and forecast 2022-2027 Exhibit 89: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on France - Year-over-year growth 2022-2027 (%) Exhibit 92: Data Table on France - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 93: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 97: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 98: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 99: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 100: Overview on factors of disruption 11.4 Industry risks Exhibit 101: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 102: Vendors covered 12.2 Market positioning of vendors Exhibit 103: Matrix on vendor position and classification 12.3 AbbVie Inc. Exhibit 104: AbbVie Inc. - Overview Exhibit 105: AbbVie Inc. - Product / Service Exhibit 106: AbbVie Inc. - Key news Exhibit 107: AbbVie Inc. - Key offerings 12.4 Afaxys Pharma LLC Exhibit 108: Afaxys Pharma LLC - Overview Exhibit 109: Afaxys Pharma LLC - Product / Service Exhibit 110: Afaxys Pharma LLC - Key offerings 12.5 Bayer AG Exhibit 111: Bayer AG - Overview Exhibit 112: Bayer AG - Business segments Exhibit 113: Bayer AG - Key news Exhibit 114: Bayer AG - Key offerings Exhibit 115: Bayer AG - Segment focus 12.6 Combe Inc. Exhibit 116: Combe Inc. - Overview Exhibit 117: Combe Inc. - Product / Service Exhibit 118: Combe Inc. - Key offerings 12.7 Foundation Consumer Healthcare LLC Exhibit 119: Foundation Consumer Healthcare LLC - Overview Exhibit 120: Foundation Consumer Healthcare LLC - Product / Service Exhibit 121: Foundation Consumer Healthcare LLC - Key offerings 12.8 Gedeon Richter Plc Exhibit 122: Gedeon Richter Plc - Overview Exhibit 123: Gedeon Richter Plc - Business segments Exhibit 124: Gedeon Richter Plc - Key news Exhibit 125: Gedeon Richter Plc - Key offerings Exhibit 126: Gedeon Richter Plc - Segment focus 12.9 HLL Lifecare Ltd. Exhibit 127: HLL Lifecare Ltd. - Overview Exhibit 128: HLL Lifecare Ltd. - Product / Service Exhibit 129: HLL Lifecare Ltd. - Key offerings 12.10 Laboratoire HRA Pharma SAS Exhibit 130: Laboratoire HRA Pharma SAS - Overview Exhibit 131: Laboratoire HRA Pharma SAS - Product / Service Exhibit 132: Laboratoire HRA Pharma SAS - Key offerings 12.11 Lupin Ltd. Exhibit 133: Lupin Ltd. - Overview Exhibit 134: Lupin Ltd. - Product / Service Exhibit 135: Lupin Ltd. - Key news Exhibit 136: Lupin Ltd. - Key offerings 12.12 Mankind Pharma Ltd. Exhibit 137: Mankind Pharma Ltd. - Overview Exhibit 138: Mankind Pharma Ltd. - Product / Service Exhibit 139: Mankind Pharma Ltd. - Key offerings 12.13 Perrigo Co. Plc Exhibit 140: Perrigo Co. Plc - Overview Exhibit 141: Perrigo Co. Plc - Business segments Exhibit 142: Perrigo Co. Plc - Key news Exhibit 143: Perrigo Co. Plc - Key offerings Exhibit 144: Perrigo Co. Plc - Segment focus 12.14 Pfizer Inc. Exhibit 145: Pfizer Inc. - Overview Exhibit 146: Pfizer Inc. - Product / Service Exhibit 147: Pfizer Inc. - Key news Exhibit 148: Pfizer Inc. - Key offerings 12.15 Piramal Enterprises Ltd. Exhibit 149: Piramal Enterprises Ltd. - Overview Exhibit 150: Piramal Enterprises Ltd. - Business segments Exhibit 151: Piramal Enterprises Ltd. - Key offerings Exhibit 152: Piramal Enterprises Ltd. - Segment focus 12.16 Sun Pharmaceutical Industries Ltd. Exhibit 153: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 154: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 155: Sun Pharmaceutical Industries Ltd. - Key offerings 12.17 Syzygy Healthcare LLC Exhibit 156: Syzygy Healthcare LLC - Overview Exhibit 157: Syzygy Healthcare LLC - Product / Service Exhibit 158: Syzygy Healthcare LLC - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 159: Inclusions checklist Exhibit 160: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 161: Currency conversion rates for US$ 13.4 Research methodology Exhibit 162: Research methodology Exhibit 163: Validation techniques employed for market sizing Exhibit 164: Information sources 13.5 List of abbreviations Exhibit 165: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio